CLAIMS

1. A lyophilized formulation of an anti-AXL antibody-drug conjugate (AXL-ADC), the lyophilized formulation obtainable or obtained by lyophilizing an aqueous formulation comprising the AXL-ADC and one or more excipients, wherein the aqueous formulation is free of any surfactant.

2. A lyophilized formulation of an AXL-ADC, the lyophilized formulation obtainable or obtained by lyophilizing an aqueous formulation comprising the AXL-ADC and
   (a) a buffer providing for a pH of between about 5 and about 7 in the aqueous formulation;
   (b) at least one bulking agent; and
   (c) at least one non-reducing sugar which forms an amorphous phase with the ADC in solid state; and
   wherein the aqueous formulation is free of any surfactant.

3. The lyophilized formulation of any one of the preceding claims,

   wherein the aqueous formulation comprises a buffer selected from the group consisting of histidine, citrate, 2-(N-morpholino)ethanesulfonic acid (MES), succinate, glycolate, carbonic acid and phosphate, or a combination of any thereof;
   wherein the pH of the aqueous formulation is in a range from about 5 to about 7; and
   wherein the aqueous formulation comprises a buffer at a concentration of about 5 mM to about 100 mM, such as from about 10 mM to about 50 mM buffer, such as from about 20 mM to about 40 mM, such as from about 28 mM to about 32 mM, such as about 30 mM buffer.

4. The lyophilized formulation of any one of the preceding claims, comprising a bulking agent selected from mannitol, glycine, and a combination thereof.

5. The lyophilized formulation of any one of the preceding claims, wherein

   the aqueous formulation comprises a bulking agent
   at a concentration of about 1% (w/v) to about 5% (w/v), such as about 2% (w/v) to about 4% (w/v), such as from about 2.5% (w/v) to about 3.5% (w/v), such as about 3% (w/v), or
   at a concentration of about 50 mM to about 300 mM, such as from about 100 mM to about 225 mM, such as from about 150 mM to about 180 mM, such as about 165 mM.

6. The lyophilized formulation of any one of the preceding claims, comprising a non-reducing sugar selected from sucrose, trehalose, and a combination thereof.

7. The lyophilized formulation of any one of the preceding claims, wherein the aqueous formulation comprises a non-reducing sugar at

   a concentration of about 0.5% (w/v) to about 7% (w/v), such as from about 0.5% (w/v) to about 4% (w/v), such as from about 1% (w/v) to about 3% (w/v) or from about 2.5% to about 3.5%, such as about 3% (w/v) or

   a concentration of about 15 mM to about 200 mM, such as from about 15 mM to about 120 mM, such as from about 30 mM to about 90 mM, such as 80 mM to about 100 mM, such as from about 84 mM to about 92 mM sucrose, such as about 88 mM.

8. The lyophilized formulation of any one of the preceding claims, wherein the AXL-ADC concentration in the aqueous formulation is from about 5 mg/mL to about 30 mg/mL, such as from about 7 mg/mL to about 20 mg/mL, such as from about 8 mg/mL to about 15 mg/mL, such as from about 9 mg/mL to about 11 mg/mL, such as about 10 mg/mL.

9. The lyophilized formulation of any one of the preceding claims, wherein the pH of the aqueous formulation is in a range from about 5.5 to about 6.5, such as from about 5.8 to about 6.2, such as about 6.

10. A lyophilized formulation obtainable or obtained by lyophilizing an aqueous formulation having a pH of about 5 to about 7 and comprising
    (a) from about 5 mg/mL to about 30 mg/mL of an AXL-ADC and
    (b) from about 10 mM to about 50 mM histidine;
    (c) from about 15 mM to about 120 mM sucrose or trehalose; and
    (d) from about 150 mM to about 180 mM mannitol or glycine.

11. The lyophilized formulation of any one of the preceding claims, wherein the AXL-ADC comprises a cytotoxic agent linked to the antibody with a cleavable linker, such as *N*-succinimydyl 4-(2-pyridyldithio)-pentanoate (SSP), maleimidocaproyl-valine-citrulline-*p*-aminobenzyloxycarbonyl (mc-vc-PAB) or AV-1 K-lock valine-citrulline.

12. The lyophilized formulation of any one of the preceding claims, wherein the AXL-ADC comprises a cytotoxic agent selected from the group consisting of DNA-targeting agents, e.g. DNA alkylators and cross-linkers, such as calicheamicin, duocarmycin, rachelmycin (CC-1065), pyrrolo[2,1-c][1,4] benzodiazepines (PBDs), and indolinobenzodiazepine (IGN); microtubule-targeting agents, auristatin, such as monomethylauristatin E (MMAE) and monomethylauristatin F (MMAF), dolastatin, maytansine, *N*(2')-deacetyl-*N*(2')-(3-marcapto-1-oxopropyl)-maytansine (DM1), and tubulysin; and nucleoside analogs; or an analogs, derivatives, or prodrugs thereof.

13. The lyophilized formulation of any one of claims 1 to 10, wherein the linker is mc-vc-PAB and the cytotoxic agent is MMAE.

14. A pharmaceutical formulation of an AXL-ADC obtained or obtainable by reconstituting the lyophilized formulation of any one of the preceding claims in a sterile aqueous diluent.

15. A pharmaceutical formulation having a pH of about 5 to about 7 and comprising, in aqueous solution:
    (a) from about 5 mg/mL to about 30 mg/mL of an AXL-ADC and
    (b) from about 10 mM to about 50 mM histidine;
    (c) from about 15 mM to about 120 mM sucrose or trehalose; and
    (d) from about 50 mM to about 300 mM mannitol or glycine.

16. The pharmaceutical formulation of claim 15, having a pH in the range of about 5.5 to about 6.5 and comprising:
    (a) from about 9 mg/mL to about 11 mg/mL AXL-ADC, such as about 10 mg/mL of the AXL-ADC;
    (b) from about 20 mM to about 40 mM histidine, such as about 30 mM histidine;
    (c) from about 80 mM to about 100 mM sucrose, such as about 88 mM sucrose; and
    (d) from about 150 mM to about 180 mM mannitol, such as about 165 mM;
    wherein the formulation is free of any surfactant.

17. An aqueous formulation of an anti-AXL antibody, comprising one or more pharmaceutically acceptable excipients, wherein the aqueous formulation is free of any surfactant.

18. An aqueous formulation of an anti-AXL antibody, comprising a buffer and at least one stabilizer, wherein the pH of the aqueous formulation is between about 5 and about 7 and wherein the aqueous formulation is free of any surfactant.

19. The aqueous formulation of any one of claims 17 and 18, comprising a buffer selected from the group consisting of histidine, citrate, MES, phosphate, carbonic acid, succinate, glycolate, or a combination of any thereof, wherein

    the buffer is at a concentration of about 10 mM to about 50 mM, such as from about 20 mM to about 40 mM buffer, such as from about 28 mM to about 34 mM, such as from about 29 mM to about 31 mM, such as about 30 mM, and

    the pH of the aqueous formulation is in a range from about 5.5 to about 6.5, such as from about 5.8 to about 6.2.

20. The aqueous formulation of any one of claims 17 to 19, comprising a stabilizer selected from the group consisting of mannitol, sucrose and trehalose, wherein the stabilizer is present at

a concentration of about 20 mM to about 400 mM, such as from about 30 mM to about 300 mM, such as from about 40 mM to about 80 mM, such as about 50 mM to about 60 mM, such as about 55 mM or

a concentration of about 0.4% (w/v) to about 7% (w/v), such as about 0.5% to about 5%, such as about 0.7% to about 1.5%, such as about 1%..

21. The aqueous formulation of any one of claims 17 to 20, which is free of any one or more of arginine, glycine, glutamic acid, sorbitol, trehalose, sucrose and sodium chloride.

22. The aqueous formulation of any one of claims 17 to 21, wherein the antibody concentration is from about 5 mg/mL to about 40 mg/mL, such as from about 8 mg/mL to about 35 mg/mL, such as from about 10 mg/mL to about 30 mg/mL, such as from about 15 mg/mL to about 25 mg/mL, such as about 20 mg/mL.

23. The aqueous formulation of any one of claims 17 to 22, wherein the pH of the aqueous formulation is in a range from about 5.5 to 6.5, such as about 6.

24. An aqueous formulation having a pH of about 5 to about 7 and comprising
(a) from about 5 mg/mL to about 40 mg/mL of an anti-AXL antibody and
(b) from about 10 mM to about 50 mM histidine;
(c) from about 50 mM to about 300 mM mannitol.

25. The aqueous formulation of claim 24, which has a pH in the range of about 5.5 to about 6.5 and comprises
(a) from about 15 mg/mL to about 25 mg/mL anti-AXL antibody, such as about 20 mg/mL of the anti-AXL antibody;
(b) from about 20 mM to about 40 mM histidine, such as about 30 mM histidine;
(c) from about 50 mM to about 60 mM mannitol, such as about 55 mM,
wherein the aqueous formulation is free of any added surfactant, amino acid excipient, NaCl, or a combination of any thereof.

26. A frozen aqueous formulation of an anti-AXL antibody, obtained or obtainable by freezing the aqueous formulation of any one of claims 17 to 25.

27. The formulation of any one of the preceding claims, wherein the anti-AXL antibody or the AXL-ADC comprises at least one binding region comprising a VH region and a VL region selected from the group consisting of:

(a) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 36, 37, and 38, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39, GAS, and 40, respectively, [**107**];

(b) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 46, 47, and 48, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49, AAS, and 50, respectively, [**148**];

(c) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 114, 115, and 116, respectively, and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 117, DAS, and 118, respectively [**733**];

(d) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 51, 52, and 53, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 55, GAS, and 56, respectively [**154**];

(e) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 51, 52, and 54, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 55, GAS, and 56, respectively [**154-M103L**];

(f) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 57, 58, and 59, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 60, GAS, and 61, respectively, [**171**];

(g) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 62, 63, and 64, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 65, GAS, and 66, respectively, [**172**];

(h) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 67, 68, and 69, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 70, GAS, and 71, respectively, [**181**];

(i) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 72, 73, and 75, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 76, ATS, and 77, respectively, [**183**];

(j) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 72, 74, and 75, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 76, ATS, and 77, respectively, [**183-N52Q**];

(k) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 78, 79, and 80, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 81, AAS, and 82, respectively, [**187**];

(l) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 83, 84, and 85, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 86, GAS, and 87, respectively, [**608-01**];

(m) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 88, 89, and 90, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 91, GAS, and 92, respectively, [**610-01**];

(n) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 93, 94, and 95, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 96, GAS, and 97, respectively, [**613**];

(o) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 98, 99, and 100, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 101, DAS, and 102, respectively, [**613-08**];

(p) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 103, 104, and 105, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 106, GAS, and 107, respectively, [**620-06**];

(q) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 108, 109, and 110, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112, AAS, and 113, respectively, [**726**];

(r) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 108, 109, and 111, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112, AAS, and 113, respectively, [**726-M101L**];

(s) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 41, 42, and 43, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 44, AAS, and 45, respectively, [**140**];

(t) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 93, 94, and 95, respectively, and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 128, XAS, wherein X is D or G, and 129, respectively, [**613 / 613-08**];

(u) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 46, 119, and 120, respectively; and a VL region comprising CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49, AAS, and 50, respectively, [**148 / 140**];

(v) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 123, 124, and 125, respectively; and a VL region comprising CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 60, GAS, and 61, respectively [**171 / 172 / 181**]; and

(w) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 121, 109, and 122, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112, AAS, and 113, respectively [**726 / 187**]; and

(x) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.:93, 126, and 127, respectively; and a VL region comprising the CDR1, CDR2, and CDR3

sequences of SEQ ID Nos.: 96, GAS, and 97, respectively [**613 / 608-01 / 610-01 / 620-06**].

28. The formulation of any one of the preceding claims, wherein the anti-AXL antibody or the AXL-ADC comprises at least one binding region comprising a VH region and a VL region selected from the group consisting of VH and VL sequences at least 90%, such as at least 95%, such as at least 97%, such as at least 99%, such as 100% identical to:

(a) a VH region comprising SEQ ID No: 1 and a VL region comprising SEQ ID No: 2 [**107**];
(b) a VH region comprising SEQ ID No: 5 and a VL region comprising SEQ ID No: 6 [**148**];
(c) a VH region comprising SEQ ID No: 34 and a VL region comprising SEQ ID No: 35 [**733**]
(d) a VH region comprising SEQ ID No: 7 and a VL region comprising SEQ ID No: 9 [**154**];
(e) a VH region comprising SEQ ID No: 10 and a VL region comprising SEQ ID No: 11 [**171**];
(f) a VH region comprising SEQ ID No: 16 and a VL region comprising SEQ ID No: 18 [**183**];
(g) a VH region comprising SEQ ID No: 25 and a VL region comprising SEQ ID No: 26 [**613**];
(h) a VH region comprising SEQ ID No: 31 and a VL region comprising SEQ ID No: 33 [**726**];
(i) a VH region comprising SEQ ID No: 3 and a VL region comprising SEQ ID No: 4 [**140**];
(j) a VH region comprising SEQ ID No:8 and a VL region comprising SEQ ID No:9 [**154-M103L**];
(k) a VH region comprising SEQ ID No:12 and a VL region comprising SEQ ID No:13 [**172**];
(l) a VH region comprising SEQ ID No:14 and a VL region comprising SEQ ID No:15 [**181**];
(m) a VH region comprising SEQ ID No:17 and a VL region comprising SEQ ID No:18 [**183-N52Q**];
(n) a VH region comprising SEQ ID No:19 and a VL region comprising SEQ ID No:20 [**187**];
(o) a VH region comprising SEQ ID No:21 and a VL region comprising SEQ ID No:22 [**608-01**];
(p) a VH region comprising SEQ ID No:23 and a VL region comprising SEQ ID No:24 [**610-01**];

(q) a VH region comprising SEQ ID No:27 and a VL region comprising SEQ ID No:28 [**613-08**];

(r) a VH region comprising SEQ ID No:29 and a VL region comprising SEQ ID No:30 [**620-06**]; and

(s) a VH region comprising SEQ ID No:32 and a VL region comprising SEQ ID No:33 [**726-M101L**].

29. The formulation according to any one of claims 27 and 28, wherein the anti-AXL antibody or the AXL-ADC comprises a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 36, 37, and 38, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39, GAS, and 40, respectively [**107**].

30. The formulation according to claim 29, wherein the anti-AXL antibody or the AXL-ADC comprises a VH region comprising SEQ ID No: 1 and a VL region comprising SEQ ID No: 2 **[107]**.

31. The formulation according to any one of claims 1 to 26, wherein the anti-AXL antibody or the AXL-ADC binds to an epitope on AXL which recognized by any of the antibodies defined in claim 42.

32. The formulation according to any one of claims 1 to 26, wherein the anti-AXL antibody or the AXL-ADC binds to

an epitope within the Ig1-like domain of AXL, the epitope comprising or requiring one or more amino acids corresponding to positions L121 to Q129 or T112 to Q124 of human AXL,

an epitope within the Ig2-like domain of AXL, the epitope comprising or requiring the amino acids corresponding to position D170 or the combination of D179 and one or more amino acids corresponding to positions T182 to R190 of human AXL, or

an epitope within the FN1-like domain of human AXL, the epitope comprises or requires one or more amino acids corresponding to positions Q272 to A287 and G297 to P301 of human AXL.

33. The formulation of any one of the preceding claims, wherein the anti-AXL antibody or the antibody-moiety of the AXL-ADC comprises a heavy chain of an isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

34. The formulation of claim 33, wherein the isotype of the anti-AXL antibody or the antibody-moiety of the AXL-ADC is IgG1, optionally allotype IgG1m(f).

35. The formulation of any one of the preceding claims, wherein the anti-AXL antibody or the antibody moiety of the AXL-ADC is a full-length monoclonal antibody, such as a full-length monoclonal IgG1,κ antibody.

36. A lyophilized formulation obtainable or obtained by lyophilizing an aqueous formulation comprising

about 9 mg/mL to about 11 mg/mL of an AXL-ADC, and

pharmaceutically acceptable excipients comprising:

about 30 mM histidine buffer providing for a pH of about 5 to about 7;

about 88 mM sucrose; and

about 165 mM mannitol;

wherein the anti-AXL antibody moiety of the ADC comprises

(a) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 36, 37, and 38, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39, GAS, and 40, respectively, [**107**];

(b) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 46, 47, and 48, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49, AAS, and 50, respectively, [**148**];

(c) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 114, 115, and 116, respectively, and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 117, DAS, and 118, respectively [**733**];

(d) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 51, 52, and 53, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 55, GAS, and 56, respectively [**154**];

(e) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 51, 52, and 54, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 55, GAS, and 56, respectively [**154-M103L**];

(f) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 57, 58, and 59, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 60, GAS, and 61, respectively, [**171**];

(g) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 62, 63, and 64, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 65, GAS, and 66, respectively, [**172**];

(h) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 67, 68, and 69, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 70, GAS, and 71, respectively, [**181**];

(i) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 72, 73, and 75, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 76, ATS, and 77, respectively, [**183**];

(j) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 72, 74, and 75, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 76, ATS, and 77, respectively, [**183-N52Q**];

(k) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 78, 79, and 80, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 81, AAS, and 82, respectively, [**187**];

(l) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 83, 84, and 85, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 86, GAS, and 87, respectively, [**608-01**];

(m)a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 88, 89, and 90, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 91, GAS, and 92, respectively, [**610-01**];

(n) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 93, 94, and 95, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 96, GAS, and 97, respectively, [**613**];

(o) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 98, 99, and 100, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 101, DAS, and 102, respectively, [**613-08**];

(p) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 103, 104, and 105, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 106, GAS, and 107, respectively, [**620-06**];

(q) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 108, 109, and 110, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112, AAS, and 113, respectively, [**726**];

(r) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 108, 109, and 111, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112, AAS, and 113, respectively, [**726-M101L**];

(s) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 41, 42, and 43, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 44, AAS, and 45, respectively, [**140**];

(t) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 93, 94, and 95, respectively, and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 128, XAS, wherein X is D or G, and 129, respectively, [**613 / 613-08**];

(u) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 46, 119, and 120, respectively; and a VL region comprising CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49, AAS, and 50, respectively, [**148 / 140**];

(v) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 123, 124, and 125, respectively; and a VL region comprising CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 60, GAS, and 61, respectively [**171 / 172 / 181**]; and

(w) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 121, 109, and 122, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112, AAS, and 113, respectively [**726 / 187**]; and

(x) a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.:93, 126, and 127, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 96, GAS, and 97, respectively [**613 / 608-01 / 610-01 / 620-06**]:

wherein the linker is mc-vc-PAB and the cytotoxic agent is MMAE, or wherein the linker is SSP and the cytotoxic agent is DM1.

37. The lyophilized formulation of claim 36, wherein the aqueous formulation consists essentially of

about 9 mg/mL to about 11 mg/mL of an AXL-ADC, and

pharmaceutically acceptable excipients comprising:

about 30 mM histidine buffer providing for a pH of about 5.5 to about 6.5;

about 88 mM sucrose; and

about 165 mM mannitol.

38. The lyophilized formulation of any one of claims 36 and 37, wherein the anti-AXL antibody moiety of the ADC comprises a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 36, 37, and 38, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39, GAS, and 40, respectively, [**107**].

39. The lyophilized formulation of claim 38, wherein the anti-AXL antibody moiety of the ADC comprises a VH region comprising SEQ ID No: 1 and a VL region comprising SEQ ID No: 2 **[107]**.

40. The lyophilized formulation of any one of claims 36 to 39, wherein the linker is mc-vc-PAB and the cytotoxic agent is MMAE.

41. The lyophilized formulation of any one of claims 36 to 40, which contains less than 3.0 % moisture, such as less than 2.0 % moisture, such as less than 1 % moisture, or less than 0.5 % moisture.

42. The lyophilized formulation of any one of claims 36 to 41 wherein the formulation is free of any inorganic salts.

43. An aqueous formulation suitable for preparing a lyophilized formulation of an AXL-ADC and having a pH of about 5 to about 7, comprising
(a) from about 7 mg/mL to about 20 mg/mL of an AXL-ADC;
(b) about 5 mM to 100 mM histidine;
(c) about 15 mM to about 120 mM sucrose; and
(d) about 150 mM to about 180 mM mannitol.

44. The aqueous formulation of claim 43, wherein the anti-AXL antibody moiety of the ADC comprises a VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 36, 37, and 38, respectively; and a VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39, GAS, and 40, respectively, [**107**].

45. The aqueous formulation of any one of claims 43 and 44, wherein the linker is mc-vc-PAB and the cytotoxic agent is MMAE.

46. A pharmaceutically acceptable liquid formulation obtained by reconstituting the lyophilized formulation of any one of claims 36 to 42 in a sterile aqueous diluent.

47. The liquid formulation of claim 46, having a pH of about 5 to about 7 and comprising about 5 mg/mL to about 30 mg/mL AXL-ADC, about 10 mM to about 50 mM histidine; about 15 mM to about 120 mM sucrose; and about 50 mM to about 300 mM mannitol or glycine, wherein the weight ratio of mannitol to sucrose is at least about 1.

48. The liquid formulation of claim 47, comprising from about 9 mg/mL to about 11 mg/mL AXL-ADC, about 20 mM to about 40 mM histidine, about 80 mM to about 100 mM sucrose and about 150 mM to about 180 mM mannitol.

49. The liquid formulation of claim 48, comprising about 10 mg/mL AXL-ADC, about 30 mM histidine, about 88 mM sucrose and about 165 mM mannitol.

50. A method of preparing an injectable solution of an AXL-ADC, comprising the step of reconstituting the lyophilized formulation of any one of claims 62 to 71 in a sterile aqueous diluent.